Feasibility and Acceptability of Fear-Less: A Stepped-Care Program to Manage Fear of Cancer Recurrence in People with Metastatic Melanoma
Open accessThe DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Abstract
Immunotherapies and targeted therapies have revolutionised treatment of metastatic melanoma and improved survival rates. However, survivors treated with novel therapies are vulnerable to high levels of fear of cancer recurrence or progression (FCR). Existing FCR interventions have rarely been trialled in people with advanced cancer. The current study aimed to evaluate the acceptability and feasibility of Fear-Less: a stepped-care model to treat FCR in people with metastatic melanoma treated with immunotherapy or targeted therapy. Sixty-one outpatients with metastatic melanoma were screened using the Fear of Cancer Recurrence Inventory Short Form (FCRI-SF) and Fear of Progression Questionnaire Short Form (FoP-Q-SF). Survivors with subthreshold FCR were stratified to a self-management intervention while those with clinical levels of FCR were provided with an individual therapy, Conquer Fear. Survivor experience surveys and rescreening were administered post-intervention completion. Results indicated that Fear-Less was an acceptable and feasible FCR intervention. Results provided preliminary support for the potential impact of Fear-Less in reducing FCR. Fear-Less is a promising first step in providing an acceptable and feasible stepped-care model to treat FCR in survivors with metastatic disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
Larkin, J., Chiarion-Sileni, V., Gonzalez, R., Grob, J.-J., Rutkowski, P., Lao, C. D., Cowey, C. L., Schadendorf, D., Wagstaff, J., Dummer, R., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1910836 · Cited by 3,723 · cited 1×
“7% for single-agent pembrolizumab [4], 44% for single-agent nivolumab [5], and 52% for combination ipilimumab and nivolumab [5].”
BackgroundFive-year outcomes with dabrafenib plus trametinib in metastatic melanoma
Robert, C., Grob, J. J., Stroyakovskiy, D., Karaszewska, B., Hauschild, A., Levchenko, E., Chiarion Sileni, V., Schachter, J., Garbe, C., Bondarenko, I., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1904059 · Cited by 1,389
Bower, P., & Gilbody, S. (2005) · British Journal of Psychiatry · doi:10.1192/bjp.186.1.11 · Cited by 1,084 · cited 1×
“A low-intensity intervention targets mild or moderate symptoms, is readily accessible, convenient for survivors, and requires minimal specialist therapist time to deliver [27].”
BackgroundSimard, S., & Savard, J. (2009) · Supportive Care in Cancer · doi:10.1007/s00520-008-0444-y · Cited by 608 · cited 2×
“• Fear of Cancer Recurrence Inventory Short Form (FCRI-SF; [31]).”
BackgroundMethodLebel, S., Ozakinci, G., Humphris, G., Mutsaers, B., Thewes, B., Prins, J., Dinkel, A., Butow, P., & on behalf of the University of Ottawa Fear of Cancer Recurrence Colloquium attendees (2016) · Supportive Care in Cancer · doi:10.1007/s00520-016-3272-5 · Cited by 586
Tauber, N. M., O’Toole, M. S., Dinkel, A., Galica, J., Humphris, G., Lebel, S., Maheu, C., Ozakinci, G., Prins, J., Sharpe, L., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.19.00572 · Cited by 402
Self-citationMehnert, A., Herschbach, P., Berg, P., Henrich, G., & Koch, U. (2006) · Zeitschrift für Psychosomatische Medizin und Psychotherapie · doi:10.13109/zptm.2006.52.3.274 · Cited by 365 · cited 2×
“90), with evidence of construct validity [34,37].”
BackgroundFear of cancer recurrence: a systematic literature review of self‐report measures
Thewes, B., Butow, P., Zachariae, R., Christensen, S., Simard, S., & Gotay, C. (2012) · Psycho-Oncology · doi:10.1002/pon.2070 · Cited by 262 · cited 1×
“There are several measures that could be used to screen for FCR [46].”
BackgroundFear of cancer recurrence: a theoretical review and novel cognitive processing formulation
Fardell, J. E., Thewes, B., Turner, J., Gilchrist, J., Sharpe, L., Smith, A. ‘., Girgis, A., & Butow, P. (2016) · Journal of Cancer Survivorship · doi:10.1007/s11764-015-0512-5 · Cited by 247 · cited 1×
“Conquer Fear is based on the Common-Sense Model (CSM) of illness, the Self-Regulatory Executive Function model (S-REF), and Relational Frame Theory (RFT) [21].”
BackgroundSelf-citationButow, P. N., Turner, J., Gilchrist, J., Sharpe, L., Smith, A. B., Fardell, J. E., Tesson, S., O’Connell, R., Girgis, A., Gebski, V. J., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.73.1257 · Cited by 228 · cited 1×
“Of the established interventions, Conquer Fear has demonstrated efficacy in early stage disease, with post-intervention reductions in FCR maintained at 3 and 6 month follow up [14].”
BackgroundSelf-citation
Cited by
Pradhan, P., Sharpe, L., & Menzies, R. E. (2021) · Cancer Management and Research · doi:10.2147/cmar.s294114 · Cited by 60
Smith, A. ‘., Bamgboje‐Ayodele, A., Jegathees, S., Butow, P., Klein, B., Salter, M., Turner, J., Fardell, J., Thewes, B., Sharpe, L., et al. (2024) · Journal of Cancer Survivorship · doi:10.1007/s11764-022-01233-9 · Cited by 23
Self-citationKang, N., & Yu, E. (2023) · Psycho-Oncology · doi:10.1002/pon.6199 · Cited by 20
Pradhan, P., Sharpe, L., Butow, P. N., Smith, A. B., & Russell, H. (2021) · Frontiers in Psychology · doi:10.3389/fpsyg.2021.634136 · Cited by 13
Zibaite, S., Tripathee, S., Moffat, H., Elsberger, B., & Maclennan, S. (2024) · PLOS ONE · doi:10.1371/journal.pone.0312769 · Cited by 5
Metadata
- Authors
- Lynch, F. A., Katona, L., Jefford, M., Smith, A. B., Shaw, J., Dhillon, H. M., Ellen, S., Phipps-Nelson, J., Lai-Kwon, J., Milne, D., Russell, L., Dax, V., Diggens, J., Kent, H., Button-Sloan, A., Elliott, J., Shackleton, M., Burridge, H., & Ftanou, M.
- Venue
- Journal of Clinical Medicine
- Publisher
- MDPI AG
- Published
- 2020-09-14
- Volume
- 9
- Issue
- 9
- Pages
- 2969
- ISSN
- 2077-0383 (ISSN-L)
- OpenAlex
- W3086563989
- Cited by
- 42
- References
- 21
- FWCI
- 2.09
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Feasibility and Acceptability of Fear-Less: A Stepped-Care Program to Manage Fear of Cancer Recurrence in People with Metastatic Melanoma. https://app.cochat.ai/papers/10.3390/jcm9092969
- The paper
- Lynch, F. A., Katona, L., Jefford, M., Smith, A. B., Shaw, J., Dhillon, H. M., Ellen, S., Phipps-Nelson, J., Lai-Kwon, J., Milne, D., Russell, L., Dax, V., Diggens, J., Kent, H., Button-Sloan, A., Elliott, J., Shackleton, M., Burridge, H., & Ftanou, M. (2020). Feasibility and Acceptability of Fear-Less: A Stepped-Care Program to Manage Fear of Cancer Recurrence in People with Metastatic Melanoma. Journal of Clinical Medicine. https://doi.org/10.3390/jcm9092969
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.